Twinrix Market Report 2026

Twinrix Market Overview

• The Twinrix market growth in the historic period has been driven by increased global hepatitis a and b prevalence, expansion of travel medicine services • Market expansion is supported by increasing international travel volumes, expansion of adult vaccination programs • Growth Driver: Surge in Hepatitis A Cases Fueling the Growth of the Market due to Increased Need for Preventive Vaccination • North America was the largest region in 2025.

What Is Covered Under Twinrix Market?

Twinrix is a combination vaccine that protects against hepatitis A and B viruses. It is commonly administered to individuals at risk of contracting these infections, such as travelers to regions with these diseases or individuals in specific occupational settings. The main types of indications in twinrix are hepatitis A, hepatitis B, and combined immunization. Hepatitis A is a viral liver infection caused by the hepatitis A virus, typically transmitted through contaminated food or water or close contact with an infected person. It is available in intramuscular injection and pre-filled syringe formulations for both monovalent and combination vaccine compositions. It is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, catering to various end users such as adults, pediatrics, and geriatrics.

What Is The Twinrix Market Growth Forecast?

The growth in the forecast period can be attributed to increasing international travel volumes, expansion of adult vaccination programs, growing focus on preventive liver health, rising healthcare spending on vaccines, improved vaccine access through retail channels. Major trends in the forecast period include increasing adoption of combination hepatitis vaccines, rising demand from travel-related immunization, expansion of occupational health vaccination programs, growing preference for pre-filled syringe formulations, enhanced awareness of hepatitis prevention.

Global Twinrix Market Segmentation

1) By Indication: Hepatitis A, Hepatitis B, Combined Immunization 2) By Formulation: Intramuscular Injection, Pre-Filled Syringes 3) By Composition: Monovalent Vaccines, Combination Vaccines 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End User: Adult, Pediatric, Geriatric

What Are The Drivers Of The Twinrix Market?

The rise in hepatitis A cases is expected to propel the growth of the twinrix market going forward. Hepatitis A is a viral liver infection, usually spread via contaminated food or water, causing symptoms like jaundice, fatigue, and nausea. The rise in hepatitis A cases is driven by contaminated food and water, as the virus spreads through ingestion and poor sanitation increases the risk of infection. Twinrix helps prevent the rise in hepatitis A cases by providing combined vaccination against both hepatitis A and B, reducing the risk of infection in at-risk populations. For instance, in April 2025, according to the Health Security Agency UK-based government agency In the UK, hepatitis A virus infections typically number around 400 cases per year, but cases have risen, exceeding 800 in 2024. Therefore, the rising prevalence of hepatitis A and B infections drives growth in the twinrix industry. The increasing awareness of vaccination is expected to propel the growth of the twinrix market going forward. Vaccination is administering a vaccine to stimulate the immune system to develop protection against specific infectious diseases. The increasing awareness of vaccination is driven by factors including public health campaigns, educational programs, trusted healthcare recommendations, media influence, and the widespread dissemination of scientific evidence supporting vaccine safety and efficacy. Awareness of vaccination drives demand for Twinrix by increasing public knowledge of hepatitis A and B risks, promoting preventive health measures, and encouraging vaccination through travel, healthcare, and public health initiatives. For instance, in July 2025, according to the World Health Organization a Switzerland-based intergovernmental organization reported that Global DTP3 vaccine coverage reached 85% in 2024, reflecting sustained immunization efforts. HPV first-dose coverage in girls rose from 27% in 2023 to 31% in 2024, marking a notable year-over-year improvement. Therefore, increasing awareness of vaccination is driving growth in the Twinrix industry. The increase in travel and tourism is expected to propel the growth of the twinrix market going forward. Travel and tourism refer to the activities and industries associated with people traveling for leisure, business, or other purposes, including the services and experiences provided to support these journeys. The increase in travel and tourism is due to growing global connectivity, rising disposable incomes, and enhanced travel services, leading to higher tourism activities and a broader range of destinations worldwide. Twinrix is helpful for travel and tourism as it provides comprehensive protection against both hepatitis A and B infections, ensuring travelers are safeguarded against potential health risks and allowing for safer and worry-free exploration of various destinations. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, it was reported that, in 2023, UK residents took 6.3 million international business trips, up from 4.9 million in 2022. Therefore, increased travel and tourism is driving growth in the twinrix industry.

Key Players In The Global Twinrix Market

Major companies operating in the twinrix market are GlaxoSmithKline plc

Regional Insights

North America was the largest region in the twinrix market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Twinrix Market?

The twinrix market consists of sales of standard-dose, accelerated-dose, vials and combination syringe. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Twinrix Market Report 2026?

The twinrix market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the twinrix industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.